CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

By | December 19th, 2016|News|

CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1

By | November 8th, 2016|News|

Cycle Pharmaceuticals and the Cystic Fibrosis Trust partnership

By | September 22nd, 2016|News|

Health Canada grants priority review for Cycle’s nitisinone tablet filing

By | July 20th, 2016|Resource|

Cycle Pharmaceuticals opens new headquarters in Cambridge, UK

By | April 15th, 2016|Resource|

Antonio Benedetti appointed as CEO of Cycle Pharmaceuticals

By | January 11th, 2016|News|